atrovent 0,25 mg/ml lösning för nebulisator
boehringer ingelheim international gmbh - ipratropiumbromid (monohydrat) - lösning för nebulisator - 0,25 mg/ml - ipratropiumbromid (monohydrat) 0,261 mg aktiv substans - ipratropiumbromid
atrovent 0,5 mg/ml lösning för nebulisator
boehringer ingelheim international gmbh - ipratropiumbromid (monohydrat) - lösning för nebulisator - 0,5 mg/ml - ipratropiumbromid (monohydrat) 0,522 mg aktiv substans - ipratropiumbromid
atrovent 0,25 mg/ml lösning för nebulisator
2care4 aps - ipratropiumbromid (monohydrat) - lösning för nebulisator - 0,25 mg/ml - ipratropiumbromid (monohydrat) 0,261 mg aktiv substans
medicinsk luft air liquide 100 % medicinsk gas, komprimerad
air liquide santé international - luft, medicinsk - medicinsk gas, komprimerad - 100 % - luft, medicinsk 100 % aktiv substans - medicinsk luft
medicinsk luft nippon gases scandinavia 100 % medicinsk gas, komprimerad
nippon gases norge as - luft, medicinsk - medicinsk gas, komprimerad - 100 % - luft, medicinsk 100 % aktiv substans - medicinsk luft
medicinsk luft strandmollen 100 % medicinsk gas, komprimerad
strandmøllen a/s - luft, medicinsk - medicinsk gas, komprimerad - 100 % - luft, medicinsk 100 % aktiv substans - medicinsk luft
rifampicin orifarm 300 mg kapsel, hård
orifarm ab - rifampicin - kapsel, hård - 300 mg - rifampicin 300 mg aktiv substans; propylenglykol hjälpämne; laktosmonohydrat hjälpämne - rifampicin
rifampicin ebb 300 mg kapsel, hård
ebb medical ab - rifampicin - kapsel, hård - 300 mg - laktosmonohydrat hjälpämne; propylenglykol hjälpämne; rifampicin 300 mg aktiv substans - rifampicin
rifampicin ebb 300 mg kapsel, hård
ebb medical ab - rifampicin - kapsel, hård - 300 mg - propylenglykol hjälpämne; rifampicin 300 mg aktiv substans; laktosmonohydrat hjälpämne - rifampicin
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.